MDCX on Nasdaq
Medicus Pharma Ltd.
Canadian pharmaceutical preparations company based in Toronto. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerMDCX on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersToronto, Canada2
- Incorporated inOntario, Canada3
- Business address300 Conshohocken State Rd., Suite 200, W. Conshohocken, Pa 194283
- Filer category, Emerging growth company3
- Legal formCorporation2
- LEI984500563DE3E95582042
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered address100 King St W Suite 3400, M5X 1A4 Toronto, Canada2
- Registered withMinistry of Government and Consumer Services, 17678522
See how the biggest companies compare on our leaderboards
Our company (formerly, Interactive Capital Partners Corporation) was incorporated pursuant to the Business Corporations Act (Ontario) on April 30, 2008 under the name Interactive Capital Partners Corporation.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administrative | $17.9M | $7.7M |
| Research and development | $7.7M | $3.5M |
| In-process research and development (IPR&D) -Teverelix | $8.7M | $0 |
| Total operating expenses | $34.4M | $11.2M |
| Loss from operations | -$34.4M | -$11.2M |
| Interest income (expense) | -$197.4K | $25.4K |
| Loss on SEPA settlements | -$278.9K | $0 |
| Change in fair value of debentures | -$583.8K | $0 |
| Loss on extinguishment of debentures | -$25.0K | $0 |
| Total other income (expense) | -$1.1M | $25.4K |
| Net loss for the year | -$35.4M | -$11.2M |
| Deemed dividend on warrant inducement | -$11.8M | $0 |
| Net loss for the year attributable to common shareholders | -$47.3M | -$11.2M |
| Foreign currency translation adjustment | -$10.7K | $0 |
| Comprehensive loss for the year attributable to common shareholders | -$47.3M | -$11.2M |
| Common shareholders of the Company | -$47.3M | -$11.2M |
| Non-controlling interests | -$146 | $0 |
| Common shareholders of the Company | -$47.3M | -$11.2M |
| Non-controlling interests | -$150 | $0 |
| Net loss per share attributable to common shareholders - basic | -$2.74 | -$1.16 |
| Net loss per share attributable to common shareholders - diluted | -$2.74 | -$1.16 |
| Weighted average number of common shares outstanding - basic | 17.3M shares | 9.6M shares |
| Weighted average number of common shares outstanding - diluted | 17.3M shares | 9.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $8.7M | $4.2M | ||
| Prepaid expenses and other current assets | $1.1M | $1.2M | ||
| Deferred financing costs | $99.3K | $0 | ||
| Total current assets | $9.9M | $5.4M | ||
| Operating lease right-of-use assets | $170.7K | $268.6K | ||
| Total assets | $10.1M | $5.6M | ||
| Accounts payable | $3.4M | $1.3M | ||
| Accrued expenses and other current liabilities | $995.3K | $762.8K | ||
| Related party payable | $116.5K | $142.5K | ||
| Operating lease liability, current | $145.5K | $116.3K | ||
| Debentures | $5.2M | $0 | ||
| Total current liabilities | $9.9M | $2.3M | ||
| Loan payable | $25.9K | $0 | ||
| Operating lease liability, non-current | $60.1K | $205.9K | ||
| Total liabilities | $10.0M | $2.5M | ||
| Common shares, no par value; 25,176,303 and 11,816,721 shares authorized, issued and outstanding at December 31, 2025 and 2024, respectively | $57.1M | $30.5M | ||
| Common shares to be issued | $313.9K | $0 | ||
| Additional paid-in capital | $6.9M | $1.5M | ||
| Accumulated other comprehensive income | $10.9K | $0 | ||
| Accumulated deficit | -$64.3M | -$28.9M | ||
| Total shareholders' equity attributable to Medicus Pharma Ltd. | -$67.6K | $3.1M | ||
| Non-controlling interests | $104.9K | $0 | ||
| Total shareholders' equity | $37.3K | $3.1M | $1.1M | |
| Total liabilities and shareholders' equity | $10.1M | $5.6M | ||
| Common Stock, No Par Value | $0 | $0 | ||
| Common stock, Shares, Authorized | 25.2M shares | 11.8M shares | ||
| Common Stock, Shares, Issued | 25.2M shares | 11.8M shares | 10.8M shares | |
| Common Stock, Shares, Outstanding | 25.2M shares | 11.8M shares | 10.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $8.7M | $4.2M | ||
| Prepaid expenses and other current assets | $1.1M | $1.2M | ||
| Deferred financing costs | $99.3K | $0 | ||
| Total current assets | $9.9M | $5.4M | ||
| Operating lease right-of-use assets | $170.7K | $268.6K | ||
| Total assets | $10.1M | $5.6M | ||
| Accounts payable | $3.4M | $1.3M | ||
| Accrued expenses and other current liabilities | $995.3K | $762.8K | ||
| Related party payable | $116.5K | $142.5K | ||
| Operating lease liability, current | $145.5K | $116.3K | ||
| Debentures | $5.2M | $0 | ||
| Total current liabilities | $9.9M | $2.3M | ||
| Loan payable | $25.9K | $0 | ||
| Operating lease liability, non-current | $60.1K | $205.9K | ||
| Total liabilities | $10.0M | $2.5M | ||
| Common shares, no par value; 25,176,303 and 11,816,721 shares authorized, issued and outstanding at December 31, 2025 and 2024, respectively | $57.1M | $30.5M | ||
| Common shares to be issued | $313.9K | $0 | ||
| Additional paid-in capital | $6.9M | $1.5M | ||
| Accumulated other comprehensive income | $10.9K | $0 | ||
| Accumulated deficit | -$64.3M | -$28.9M | ||
| Total shareholders' equity attributable to Medicus Pharma Ltd. | -$67.6K | $3.1M | ||
| Non-controlling interests | $104.9K | $0 | ||
| Total shareholders' equity | $37.3K | $3.1M | $1.1M | |
| Total liabilities and shareholders' equity | $10.1M | $5.6M | ||
| Common Stock, No Par Value | $0 | $0 | ||
| Common stock, Shares, Authorized | 25.2M shares | 11.8M shares | ||
| Common Stock, Shares, Issued | 25.2M shares | 11.8M shares | 10.8M shares | |
| Common Stock, Shares, Outstanding | 25.2M shares | 11.8M shares | 10.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss for the year | -$35.4M | -$11.2M |
| Stock-based compensation expense | $1.5M | $713.1K |
| Non-cash interest expense | $429.1K | $74.0K |
| Change in operating lease right-of-use assets | $97.8K | $88.2K |
| Change in fair value of debentures | $583.8K | $0 |
| Loss of extinguishment of debentures | $25.0K | $0 |
| IPR&D - Teverelix | $8.7M | $0 |
| Foreign exchange gain/loss | $41.9K | $0 |
| Loss on SEPA settlements | $278.9K | $0 |
| Issuance cost related to SEPA | $300.0K | $0 |
| Cost of issuance of debentures | $111.7K | $0 |
| Prepaid expenses | $352.8K | -$1.0M |
| Deferred financing costs | -$99.3K | $0 |
| Accounts payable | $923.6K | $808.7K |
| Accrued expenses and other current liabilities | -$438.8K | $358.0K |
| Operating lease liability | -$142.6K | -$70.1K |
| Related party payable | -$26.0K | -$23.5K |
| Net cash used in operating activities | -$22.8M | -$10.2M |
| Proceeds from issuance of convertible promissory notes | $0 | $5.2M |
| Proceeds from initial public offering, net of offering expenses | $0 | $2.0M |
| Proceeds from issuance of common shares and warrants, net of issuance costs | $9.8M | $5.5M |
| Proceeds from issuance of debentures | $11.9M | $0 |
| Repayment of the debentures and other loan | -$7.4M | $0 |
| Proceeds from issuance of common shares under SEPA | $8.4M | $0 |
| Proceeds from exercise of warrants | $9.9M | $0 |
| Proceeds from exercise of stock options | $162.4K | $0 |
| Costs to issue debentures | -$136.7K | $0 |
| Issuance costs for common shares | -$653.5K | $0 |
| Net cash provided by financing activities | $31.9M | $12.7M |
| Net cash paid for Antev asset acquisition including transaction costs | -$4.6M | $0 |
| Net cash used in investing activities | -$4.6M | $0 |
| Foreign currency effect on cash and cash equivalents | -$3.0K | $0 |
| Net increase in cash and cash equivalents during the year | $4.5M | $2.4M |
| Cash paid for interest | $221.7K | $40.6K |
| Right-of-use assets obtained in exchange for lease liabilities | $0 | $356.8K |
| Deemed dividend on warrant inducement | $11.8M | $0 |
| Issuance costs included in accounts payable | $95.4K | $265.0K |
| Shares issued for Antev asset acquisition | $2.1M | $0 |
| Shares to be issued for Antev asset acquisition | $313.9K | $0 |
| Issuance of shares related to SEPA agreement | $300.0K | $0 |
| Accrued interest converted into common shares | $0 | $38.5K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Medicus Pharma Ltd., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerRaza Bokhari Dec 31, 2024 to now9
- PresidentCarolyn F. Bonner Dec 31, 2024 to now10
- Chief financial officerCarolyn F. Bonner Dec 18, 2025 to now11
- Chief financial officerJames P. Quinlan Dec 31, 2024 to Dec 18, 202512
- Chief operating officerAndrew Alasdair Smith Jul 3, 2025 to now13
Board members and other officers (12)
- Chief Scientific OfficerEdward J. Brennan Dec 31, 2024 to now14
- Chief Medical OfficerFaisal Mehmud Dec 31, 2024 to now15
- Board memberAjay Raju Jul 24, 2025 to now16
- Board memberCathy McMorris Rodgers Jul 31, 2025 to now17
- Board memberPatrick J. Mahaffy Sep 8, 2025 to now18
- Board memberBarry Fishman Dec 31, 2024 to now19
- Board memberFrank W. Lavelle Dec 31, 2024 to Jan 23, 202520
- Board memberLarry Kaiser Dec 31, 2024 to now21
- Board memberRaza Bokhari Dec 31, 2024 to now9
- Board memberRobert J. Ciaruffoli Dec 31, 2024 to now22
- Board memberSara R. May Dec 31, 2024 to now23
- Board memberWilliam Ashton Dec 31, 2024 to now24
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Chief Operating OfficerErica J. Monaco named Jul 8, 202425
Timeline
Filings
334 filings to the SEC since October 2021: 4 annual reports, 5 quarterly reports, 33 major events, 83 insider forms, 11 large holders, 3 private raises, 195 other. The latest 20:
- Oct 7, 2026424B3 EDGAR
- Oct 7, 20268-K EDGAR
- Sep 14, 2026424B3 EDGAR
- Sep 14, 20268-K EDGAR
- Sep 14, 2026SCHEDULE 13D EDGAR
- Sep 11, 20268-K EDGAR
- Sep 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 3, 2026424B3 EDGAR
- Sep 3, 20268-K EDGAR
- Aug 13, 2026424B3 EDGAR
- Aug 12, 202610-Q EDGAR
- Jun 4, 2026424B3 EDGAR
- Jun 4, 20268-K EDGAR
- Jun 4, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 4, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 4, 20264 OWNERSHIP DOCUMENT EDGAR
The 334 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 20, 2025 | Melani Kenneth R.10% owner | Sale | 75,000 | $7.72 | $579.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Raza BokhariSCHEDULE 13D, 3 filings Feb 10, 2025 to Sep 14, 202626
- Ajay RajuSCHEDULE 13G/A, 2 filings Jan 13, 2025 to May 5, 202627
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings May 15, 2025 to Aug 14, 202528
- John Jason HathawaySCHEDULE 13G/A, 2 filings Feb 10, 2025 to Aug 12, 202529
- Kenneth R. MelaniSCHEDULE 13G/A, 2 filings Feb 13, 2025 to Aug 12, 202530
Money raised
Private offerings the company reported to the SEC on Form D.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARCarolyn F. Bonner, President
- 11
- 12
- 13
- 14
- 15SEC EDGARFaisal Mehmud, Chief Medical Officer
- 16SEC EDGARAjay Raju, Board member
- 17SEC EDGARCathy McMorris Rodgers, Board member
- 18SEC EDGARPatrick J. Mahaffy, Board member
- 19SEC EDGARBarry Fishman, Board member
- 20SEC EDGARFrank W. Lavelle, Board member
- 21SEC EDGARLarry Kaiser, Board member
- 22SEC EDGARRobert J. Ciaruffoli, Board member
- 23SEC EDGARSara R. May, Board member
- 24SEC EDGARWilliam Ashton, Board member
- 25
- 26
- 27
- 28
- 29
- 30